Code Biotherapeutics

Code Biotherapeutics is a privately-held biotechnology company that specializes in the development of innovative genetic medicines. Their mission is to address the significant unmet needs of patients suffering from debilitating genetic diseases by pioneering the use of their proprietary 3DNA® platform. This non-viral, multivalent synthetic DNA delivery platform has been engineered to overcome many of the limitations associated with viral-based gene therapies, such as immunogenicity, gene size limitations, re-dosability issues, and manufacturing complexity.

Code Bio is advancing an internal pipeline focused on select rare disease programs, including Duchenne Muscular Dystrophy (DMD), Type 1 Diabetes (T1D), and other serious diseases, while also actively seeking collaborative partnerships to extend the reach of their platform and develop therapies for both rare and prevalent diseases. Their 3DNA platform offers the potential for highly targeted, titratable, and re-dosable genetic medicines, providing hope for patients with a wide range of genetic disorders.

Code Biotherapeutics offers flexible work arrangements, including remote working opportunities when applicable. This, combined with a generous time off policy and a week off at the end of the year for recharging, demonstrates their commitment to work-life balance and employee well-being.

Code Biotherapeutics offers a comprehensive benefits package designed to support employees' well-being and financial security. Benefits include a competitive base salary with annual incentive opportunities, equity participation, comprehensive health and welfare plans (including medical, dental, vision, life, disability, and accident insurance), wellness and recognition programs, paid time off and holidays, a week off at the end of the year for recharging, flexible work arrangements, and an environment where professional development is actively encouraged.

Code Biotherapeutics is a biotechnology company focused on developing and delivering novel, non-viral genetic medicines to treat and potentially cure serious and life-threatening genetic diseases. They leverage their proprietary 3DNA platform, which is designed to overcome the challenges of viral-based gene therapies by offering improved cell targeting, bioavailability, modularity, and the ability to deliver larger genetic payloads. Code Bio is committed to advancing an internal pipeline of therapies focused on a variety of diseases, while also pursuing strategic partnerships to expand their reach and impact.

Code Biotherapeutics fosters a collaborative and fast-paced work environment where employees are encouraged to think creatively and act with a sense of urgency. The company values diversity of thought, open communication, and teamwork, recognizing the importance of a dynamic and agile workforce to achieve breakthroughs in genetic medicine. Code Bio is committed to fostering a culture that is inclusive and socially responsible, recognizing the importance of a diverse workforce in driving innovation.

Code Biotherapeutics is committed to fostering a diverse, equitable, and inclusive work environment that reflects the communities it serves. They believe in creating a culture where all employees feel valued, respected, and empowered to contribute their unique perspectives and talents. Code Bio actively seeks to attract, develop, and retain a workforce that represents the diversity of its stakeholders and embraces different backgrounds, experiences, and identities. This commitment extends beyond internal practices, recognizing that their innovative genetic medicines hold the potential to benefit diverse patient populations.